New injection could help nasal polyp sufferers avoid surgery
NCT ID NCT06516302
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an experimental drug called GR1802 for adults with severe chronic rhinosinusitis with nasal polyps. The goal is to see if the drug can shrink polyps, ease congestion, and reduce the need for surgery or steroids. 228 participants will receive either GR1802 or a placebo every two weeks for 13 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GR1802 (an experimental drug given as an injection)
What this could lead to
If it works, this could provide a new treatment option for people with severe nasal polyps, potentially reducing the need for surgery and steroid use.
What could go wrong
This is still an experimental drug in a Phase 3 trial. It may not work better than placebo, and side effects are possible. Results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, China